OneChain's CAR T trial treats its first cortical T-cell ALL patient pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
Bone Therapeutics announces 2021 full year results Strategic focus revised and fully focused on achieving topline results of the ALLOB Phase IIb study in tibial fracturesDiscussions for ALLOB global partnership still ongoingBoard of Directors and Management exploring all strategic options to protect shareholder.
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it is redefining its strategic priorities to concentrate specifically on the development of its most advanced clinical asset, the allogeneic cell therapy .
Bone Therapeutics to participate in upcoming conferences
Search jobs
Bone Therapeutics to participate in upcoming conferences
Gosselies, Belgium, 20 May 2021, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that its management will provide contributions to the following scientific, business and investor conferences in Q2 2021 and on the following ranges of topics:
• International Society for Cell & Gene Therapy (ISCT) Annual Meeting (26-28 May 2021): Anthony Ting, PhD, Chief Scientific Officer, will give two presentations titled:
- Industry-sponsored cell therapy trials for COVID-19 induced ARDS – An update
- Naming Cell & Gene Therapies: Harmonizing with INN Nomenclature and Regulatory Impacts – Industry Perspective